胰腺导管腺癌面临的挑战与最新研究进展

Challenges and recent research progress in pancreatic ductal adenocarcinoma

胰腺导管腺癌(pancreatic ductal adenocarcinoma,PDAC)是全球死亡率最高的恶性肿瘤之一。虽然手术切除是治疗PDAC的重要手段之一,但基于手术切除的治疗策略在过去的25年中并未显著提高患者的生存率。当发生转移时,FOLFIRINOX以及基于吉西他滨的联合治疗只能略微延长患者的生存时间。不仅如此,近年来取得重要突破的免疫疗法在PDAC患者上的表现也乏善可陈,因此亟需探索新型的治疗手段。该文将就PDAC面临的挑战以及研究进展展开综述。

Pancreatic ductal adenocarcinoma(PDAC)is still one of the deadliest malignancies in the world.Although surgery remains the only curative treatment for pancreatic cancer,therapeutic strategies based on initial resection have not substantially improved the survival of patients with resectable disease over the past 25 years.In the metastatic setting,FOLFIRINOX,and drugs plus gemcitabine have yielded only modest improvements in survival.Besides,immunotherapy,which has made important breakthroughs in recent years,also performs poorly in patients with PDAC.Thus,new treatments are urgently needed for patients with PDAC.Here we review the current challenges facing PDAC and the upcoming novel therapeutics that hold promise for this disease.